The Ministry of Ayush (Ayurveda, Yoga, Naturopathy, Unani, Siddha, Sowa-Rigpa and Homoeopathy) will be introducing the clinical repository portal along with a mobile application of Ayush Sanjivani in an event on Thursday. The portal will display the required information about the clinical outcomes of the alternative therapy along with further research and analysis.
In a virtual event, Kiren Rijiju, Union minister of state (independent charge) for Ayush, will be inaugurating the Ayush Clinical Case Repository (ACCR) portal and also the third version of the Ayush Sanjivani app.
In a statement, the Ayush Ministry said, “The Ayush Clinical Repository (ACCR) portal (https://accr.ayush.gov.in/) will serve as a platform to support both Ayush practitioners and general public. This portal aims to aggregate information about clinical outcomes achieved by Ayush practitioners on a large scale. It will facilitate not just dissemination of information but also further analysis and research. It is expected to document the strengths of Ayush systems for treatment of various disease conditions.”
The portal will be a benefit for the practitioner community, and the public and further widen the horizon of the scientific base of all the departments of Ayush.
The Ayush Sanjivani application is available for downloads on both Google Play Store and iOS. The third version supports the study and documentation adhering to the efficacy of the specific Ayush interventions.
- Melukote – Vairamudi Festival – 2022
- Bengaluru metro to function on weekdays, closed on weekends from July 1
- India provides reciprocal exemption of EU Digital COVID Certificate to include Covishield, Covaxin
- PM Modi will address the Digital India beneficiaries at 11 am tomorrow
- Pvt hospitals will obtain Covid vaccine doses via CoWIN starting from July 1
Niti Aayog presents the list of names private sector banks for privatization
India’s first indigenous home-based self-testing Covid-19 kit launched commercially
DCGI waiver will bring foreign Covid-19 vaccines of Pfizer, Moderna one step closer